Long-term Safety and Effectiveness of Levodopa-carbidopa Intestinal Gel Infusion

Long-term Safety and Effectiveness in Motor and Non-motor Symptoms of Levodopa-carbidopa Intestinal Gel Infusion in Advanced Parkinson's Disease Patients With Motor Fluctuations

Levodopa-carbidopa intestinal gel (LCIG) infusion has demonstrated to improve motor fluctuations. The aim of this study is to assess the long-term safety and effectiveness of LCIG infusion in advanced Parkinson's disease (PD) patients with motor fluctuations and its effect in non-motor symptoms.

Study Overview

• Status: Unknown
• Conditions: Parkinson Disease

Detailed Description

The following parameters were analyzed prior to LCIG treatment (at baseline), at months one, three, six and twelve, and every year afterwards over a 10-year period:

• Safety:

  - Adverse Events (AEs) related to percutaneous endoscopic gastrostomy (PEG) procedures and gastrostomy, infusion device, and treatment. Actions taken to solve them, and reasons for treatment discontinuation and withdrawal.

• Effectiveness:

  • Motor fluctuations: Off time in hours recorded in Parkinson's Disease Diary©.
  • Dyskinesia and other motor clinical aspects: evaluated with the Unified Parkinson's Disease Rating Scale (UPDRS) part IV, UPDRS part II in On and Off, UPDRS part III in On and Off, Hoehn and Yahr (H&Y) stage in On and Off and Schwab and England (S&E) scale.
  • Non-motor clinical aspects: cognitive function through Mini Mental State Examination (MMSE), and UPDRS part I, and relevant neuropsychiatric disorders.

The parameters analyzed in the three prospective substudies carried out in three subsets of this population, are described below:

Substudy 1 - Cognition and behavior assessment: Subgroup evaluated with a specific neuropsychological battery for assessment of cognition and behavior disorders prior to treatment (at baseline) and after 6 months of LCIG, by the same neuropsychologist at the same environmental conditions and in patients in phase On. The cognitive examination included: tests that assessed cognitive areas affected in PD according to the literature, psychometric tests with well-known parameters, tests that can be used in different types of populations (neurologic and psychiatric disorders, screening, etc.), tests suitable for a population with low educational and cultural level.

• Attentional function: Forward Digit Span test of Weschler Adult Intelligence Scale-Third Edition (WAIS III); Audio-verbal attentional capacity; and Stroop Color-Word test.
• Executive functions: Backward Digit Span of WAIS III; Audio-verbal working memory; Stroop-word and Stroop-color subtests; Response inhibition capacity; Controlled Oral Word-Association Test (FAS) of phonemic verbal fluency; Category Naming Test (Animals) of semantic verbal fluency.
• Visual-constructional visuospatial and visuoperceptual functions: Clock Drawing Test - (order and copy) -visual-constructional; Reading clocks - simple visuospatial ability; Luria test of overlapping figures - visual perceptive skills function.
• Memory and learning: Rey Auditory Verbal Learning Test (RAVLT) - Short and long term audio-verbal memory and recognition.
• Language: Boston Naming Test (BNT) - Title by visual comparison.
• Motor functions: Luria motor sequences - Voluntary motor control, Motor coordination.
• Mood: Beck depression inventory (BDI)
• Behavior: Neuropsychiatric Inventory (NPI) - Exploration of psychological and behavioral symptoms.

Substudy 2 - Quality of sleep: Subgroup evaluated with Epworth scale, fatigue scale, Pittsburg quality of sleep questionnaire, Beck Depression Inventory (BDI), and Hamilton anxiety scale, administered prior to treatment (at baseline) and 6 months after treatment. In addition, an overnight polysomnography (PSG) study was carried out at these timings.

Substudy 3 - Health status, QoL and caregiver burden: Subgroup evaluated for up to 12 months, with the Spanish version of the 39-items quality of life questionnaire in PD (PDQ-39, 0-156), health status questionnaires (EQ-5D, range 5-15; and EQ-VAS range 0-100), global clinical impression scale (CGI, range 1-7), and caregiver burden questionnaire or Zarit Burden index (ZBI, range 0-100). Assessments were done prior to treatment (at baseline), 1 week, 3 months, 6 months and 12 months after treatment.

• Study Type: Observational
• Enrollment (Anticipated): 40

Contacts and Locations

• Study Contact: Name: Oriol de Fabregues, MD, PhD; Phone Number: 4258 00 34 934894258; Email: odfabregues@vhebron.net
• Study Contact Backup: Name: Inmaculada Fuentes Camps, MD; Phone Number: 4881 00 34 934894113; Email: usic@vhir.org

Study Locations

• Spain
  • Barcelona, Spain, 08035
    • Recruiting
    • Hospital Universitari Vall d'Hebron
    • Contact: Oriol de Fabregues, MD, PhD; Phone Number: 4258 00 34 934894258; Email: odfabregues@vhebron.net
    • Contact: Inmaculada Fuentes Camps, MD; Phone Number: 4881 00 34 4894113; Email: usic@vhir.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 83 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

patients with advanced PD, responders to levodopa and with disabling motor fluctuations. that fulfilled the UK Brain Bank criteria (Hughes et al., 1992) for the diagnosis of idiopathic PD and were experiencing severe motor fluctuations, which were debilitating in daily life, despite receiving optimized conventional oral medications. Patients had been previously treated with oral levodopa combined with entacapone, rasagiline, dopamine agonists and/or apomorphine injections. Patients with atypical parkinsonian features were not included.

Description

Inclusion Criteria:

1. Patients with Parkinson's Desease (PD), diagnosed according to diagnostic criteria of the Brain Bank of London - United Kingdom Parkinson's disease Society Brain Bank (Gibb and Lees 1988; Hughes, Daniel et al. 1992; Calne, Snow et al 1992 ; Daniel i Lees 1993; Gelb, Oliver et al., 1999)
2. Patients with PD who respond to levodopa, according to the doctor's opinion. When the values of clinical scales with levodopa treatment achieve a 20-30% improvement in the scores of the Unified Parkinson's Disease Rating Scale (UPDRS). (UPDRS Off - UPDRS On) / UPDRS Off (Merello, Nouzeilles et al., 2002).
3. Patients with PD with a recognized Off and On status (motor fluctuations), confirmed by Parkinson's Disease Diary © (Hauser, Friedlander et al., 2000) at the start of the study (newspapers corresponding to 3 days preceding the initial visit).
4. Patients with PD in the advanced stage with severe motor fluctuations and dyskinesia induced by levodopa, poorly controlled with conventional optimized treatment.
5. Patients with PD in the advanced stage with severe motor fluctuations and dyskinesia induced by levodopa, poorly controlled with other complex treatments (such as apomorphine infusion pumps or ECP).
6. Patients with PD in the advanced state with serious motor fluctuations that present other non-motor complications such as depressive disorder, mild cognitive disorder, pulmonary control disorder, hallucinations and psychotic disorders and episodes of sleep, of moderate severity but , which excludes them from other alternatives to complex treatments, assisted with devices, second-line antiparkinsonians.
7. Patients who are capable, they or their responsible carers and assistants, to learn the treatment with levodopa intestinal infusion and the use of their devices and to guarantee their proper functioning and correct handling.
8. Patients with PD who have been indicated and who have agreed to begin treatment with levodopa intestinal infusion.
9. Patients who have included and granted their consent to participate in the prospective study of habitual clinical practice and have signed an informed consent form to participate in the study.
10. Women who have stopped menstruation naturally 24 months before, or are surgically sterile.

11. Women of childbearing age may participate in the study provided they use a contraceptive method acceptable from a medical point of view (a stable dose of contraceptive drug for at least 3 months or barrier methods: intrauterine device, diaphragm, or combination of condoms and spermicide).

    Women who are not nursing or are pregnant. Although no human teratogenicity has been described with levodopa treatment, and carbidopa does not cross the placental barrier and does not prevent these patients from interrupting oral levodopa during pregnancy (Merchant, Cohen et al., 1994; Ball i Sagar 1995; von Graevenitz, Shulman et al. 1996; Nomoto, Kaseda et al., 1997); In the event that it is considered GILC will start after pregnancy.

12. Patients attending the external consultation of the Neurology Service (Unit of Movement Disorders) at the Vall d'Hebron University Hospital.

Exclusion Criteria:

1. Patients who do not suffer from an idiopathic PD. That is, in which the diagnosis of PD is unclear or there is suspicion that there are other Parkinson's syndromes, such as secondary parkinsonism (caused by drugs, toxins, infectious agents, vascular disease, trauma or brain neoplasms), Parkinson plus syndromes (e.g., multi systemic atrophy, progressive supranuclear paralysis, corticosteroidal degeneration) or other neurodegenerative diseases.
2. Contraindications for the use of levodopa, such as narrow angle glaucoma, pheochromocytoma, Cushing syndrome or malignant melanoma history.
3. Treatment with non-selective MAO inhibitors and selective MAO type A inhibitors. These treatments should not be administered simultaneously with levodopa intestinal infusion. They must be taken down at least two weeks before the start of the treatment.
4. Psychiatric disorders, neurological or behavioral disorders that may interfere with the capacity of the subjects to give their informed consent to participate, or interfere with the performance or interpretation of the study; This category also includes serious hallucinations.
5. Cognitive deficiencies or dementias, defined as a score <24 in the Mini Mental State Exam (MMSE) (Folstein MF, Folstein et al., 1975) or that reach the criteria for the dementia of the Diagnostic and Statistical Manual of Fourth Mental Disorders (DSM-IV) (American Psychiatric Association 2000). Except for a compelling indication that the fluctuations are seriously impaired and correct and successful treatment and supervision can be guaranteed.
6. Abnormal laboratory data of clinical importance or any abnormal laboratory value that may interfere with the evaluation of safety according to the doctor.
7. Current indications of haematological, autoimmune, endocrine, cardiovascular, renal or gastrointestinal disorders of clinical importance that could interfere with the participation of the subject in the study.
8. Background or current suffering of gastrointestinal, liver, kidney or other pathology that may interfere with the absorption, distribution, metabolism or excretion of the study's drug or its evaluation, or interfere with the introduction of the probe system.
9. Medical, laboratory or surgical problems that the doctor considers to be of clinical importance.

10. Subjects in which the placement of a GEP-J probe is contraindicated for treatment with levodopa intestinal infusion or subjects considered to be of high risk for the GEP-J procedure, according to the evaluation performed by the gastroenterologist or the surgeon.

    The contraindications for the placement of the GEP-J probe include, among others, the following processes:

    1. Pathological changes in the gastric wall.
    2. Impossibility of joining the gastric wall and the abdominal wall.
    3. Blood clotting disorders: prothrombin activity less than 60% or INR of 1.4 and platelet count less than 80,000; Anticoagulant or antiaggregant treatment is not a contraindication but should be corrected and suspended before the procedure, due to the risk of bleeding.
    4. Pneumonia or severe respiratory failure. It has been suggested that a forced vital capacity of less than 1 liter and a pCO2 greater than 45 mmHg would be associated with an unacceptable mortality with the GEP procedure.
    5. Ascites
    6. Peritonitis
    7. Acute pancreatitis.
    8. Paralytic ileus.
    9. State of immunodeficiency, neutropenia, HIV, hypogammaglobulinemia, chronic steroid therapy.

    Except in cases where the indication of treatment with levodopa intestinal infusion is manifestly necessary and will be resorted to the implantation of a surgical gastrostomy.

11. Uncooperative attitude or reasonable probability that the subject does not comply with the treatment and the procedures of the study.
12. Subjects that do not provide their informed consent in writing to participate in the study.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in motor fluctuations of the Off time.	number of hours in Off time measured with Parkinson's Disease Diary © (Hauser, Friedlander et al., 2000). Changes will be compared to basal data.	10 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in proportion of the waking day with dyskinesia	Measured with the proportion of the day (in percentage) with dyskinesia. Responding to question 32 of Unified Parkinson's Disease Rating Scale (UPDRS) part IV categorizing 5 possible percentages: 0=0%, 1=1-25%, 2=26-50%, 3=51-75%, 4=76-100%. Understanding that the highest percentage indicates more time of the day in this period (historical information). Changes will be compared to basal data.	10 years
Change in severity of dyskinesia	Measured with the level of disability caused by dyskinesia. Responding to question 33 of the Unified Parkinson's Disease Rating Scale (UPDRS) part IV that categorizes in 0: they are not disabling, 1: mildly disabling, 2: moderately disabling, 3: severely disabling and 4: they produce total disability. Changes will be compared to basal data.	10 years
Change in parkinsonian motor symptoms assessed by the Unified Parkinson's Disease Rating Scale (UPDRS)	Measured with the Unified Parkinson's Disease Rating Scale (UPDRS) ranging from 0 (normal) to 199 (highest motor disability). Changes will be compared to basal data.	10 years
Change in Sleep Quality as assessed by Epworth Sleepines Scale (ESS)	Measured with Epworth Sleepines Scale (ESS) ranging from 0 (normal) to 24 (highest sleepiness). Changes will be compared to basal data.	6 months
Change in Sleep Quality as assessed by Pittsburgh Sleep Quality Index (PSQI)	Measured with Pittsburgh Sleep Quality Index (PSQI), ranging from 0 (healthier sleep quality) to 21 (worst sleep quality). Changes will be compared to basal data.	6 months
Total sleep time	Total sleep time measured with an overnight polysomnography	One night at the sleep unit
Arousal index	number of arousals/hour of sleep measured with an overnight polysomnography	One night at the sleep unit
Sleep architecture	percentage of the different sleep phases measured with an overnight polysomnography	One night at the sleep unit
Change in cognitive function as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS)	Measured with the Unified Parkinson's Disease Rating Scale (UPDRS) Part I (mentation, behavior and mood) ranging from 0 (normal) to 16 (highest cognitive function impaired). Changes will be compared to basal data.	6 months
Change in quality of life as assessed by 39-item Parkinson's disease Quality of Life Questionnaire Summary Index (PDQ-39)	Measured with of the 39-item Parkinson's disease Quality of Life Questionnaire Summary Index (PDQ-39) ranging from 0 (normal) to 100 (worst quality of life). Changes will be compared to basal data.	1 year
Change in caregiver burden as assessed by the Zarit caregiver Burden Index (ZBI)	Measured with of the Zarit caregiver Burden Index (ZBI) ranging from 0 (no overburden) to 110 (totally overburden). Changes will be compared to basal data.	1 year
Long term treatment safety as assessed by the ocurrence of serious advers events	Collecting adverse event that causes death, threatens life, requires hospitalization or prolongs hospitalization, causes disability or constitutes an important medical event.	10 years

Collaborators and Investigators

• Sponsor: Hospital Universitari Vall d'Hebron Research Institute
• Investigators: Principal Investigator: Oriol de Fabregues, MD, PhD, Neurologist

Publications and helpful links

General Publications

• Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, Dal Fante M, Lopiano L, Pezzoli G. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord. 2007 Jun 15;22(8):1145-9. doi: 10.1002/mds.21500.
• Antonini A, Yegin A, Preda C, Bergmann L, Poewe W; GLORIA study investigators and coordinators. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Parkinsonism Relat Disord. 2015 Mar;21(3):231-5. doi: 10.1016/j.parkreldis.2014.12.012. Epub 2014 Dec 19. Erratum In: Parkinsonism Relat Disord. 2016 Oct;31:162.
• Buongiorno M, Antonelli F, Camara A, Puente V, de Fabregues-Nebot O, Hernandez-Vara J, Calopa M, Pascual-Sedano B, Campolongo A, Valldeoriola F, Tolosa E, Kulisevsky J, Marti MJ. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry. Parkinsonism Relat Disord. 2015 Aug;21(8):871-6. doi: 10.1016/j.parkreldis.2015.05.014. Epub 2015 May 19.
• Caceres-Redondo MT, Carrillo F, Lama MJ, Huertas-Fernandez I, Vargas-Gonzalez L, Carballo M, Mir P. Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease. J Neurol. 2014 Mar;261(3):561-9. doi: 10.1007/s00415-013-7235-1. Epub 2014 Jan 30.
• Catalan MJ, de Pablo-Fernandez E, Villanueva C, Fernandez-Diez S, Lapena-Montero T, Garcia-Ramos R, Lopez-Valdes E. Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease. Mov Disord. 2013 Dec;28(14):2007-10. doi: 10.1002/mds.25636. Epub 2013 Oct 10.
• Eggert K, Schrader C, Hahn M, Stamelou M, Russmann A, Dengler R, Oertel W, Odin P. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol. 2008 May-Jun;31(3):151-66. doi: 10.1097/wnf.0b013e31814b113e.
• Fasano A, Ricciardi L, Lena F, Bentivoglio AR, Modugno N. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life. Eur Rev Med Pharmacol Sci. 2012 Jan;16(1):79-89.
• Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord. 2015 Apr;30(4):500-9. doi: 10.1002/mds.26123. Epub 2014 Dec 24.
• Nyholm D, Lewander T, Johansson A, Lewitt PA, Lundqvist C, Aquilonius SM. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol. 2008 Mar-Apr;31(2):63-73. doi: 10.1097/WNF.0b013e3180ed449f.
• Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A; LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014 Feb;13(2):141-9. doi: 10.1016/S1474-4422(13)70293-X. Epub 2013 Dec 20. Erratum In: Lancet Neurol. 2014 Mar;13(3):240.
• Puente V, De Fabregues O, Oliveras C, Ribera G, Pont-Sunyer C, Vivanco R, Cucurella G, Giralt E, Delgado T, Garcia C, Seoane A, Campo R. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord. 2010 Mar;16(3):218-21. doi: 10.1016/j.parkreldis.2009.07.015. Epub 2009 Sep 16.
• Zibetti M, Merola A, Artusi CA, Rizzi L, Angrisano S, Reggio D, De Angelis C, Rizzone M, Lopiano L. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience. Eur J Neurol. 2014 Feb;21(2):312-8. doi: 10.1111/ene.12309. Epub 2013 Dec 7.

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2008
• Primary Completion (Actual): July 18, 2018
• Study Completion (Anticipated): December 31, 2018

Study Registration Dates

• First Submitted: June 27, 2018
• First Submitted That Met QC Criteria: July 18, 2018
• First Posted (Actual): July 27, 2018

Study Record Updates

• Last Update Posted (Actual): July 27, 2018
• Last Update Submitted That Met QC Criteria: July 18, 2018
• Last Verified: July 1, 2018

More Information

Terms related to this study

• Keywords: levodopa infusion
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Parkinson Disease
• Other Study ID Numbers: PR(AG)129/2008

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided
• IPD Plan Description: Clinical Study report, results and statistical analysis, study protocol may be shared

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No